1. Home
  2. ASMB vs EBS Comparison

ASMB vs EBS Comparison

Compare ASMB & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$28.45

Market Cap

440.0M

Sector

Health Care

ML Signal

HOLD

Logo Emergent Biosolutions Inc.

EBS

Emergent Biosolutions Inc.

HOLD

Current Price

$8.06

Market Cap

411.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASMB
EBS
Founded
2005
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
440.0M
411.1M
IPO Year
2010
2006

Fundamental Metrics

Financial Performance
Metric
ASMB
EBS
Price
$28.45
$8.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$44.20
$12.00
AVG Volume (30 Days)
93.4K
663.9K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
91.78
125.83
EPS
N/A
0.93
Revenue
N/A
$742,900,000.00
Revenue This Year
N/A
$1.29
Revenue Next Year
$638.39
N/A
P/E Ratio
N/A
$8.92
Revenue Growth
N/A
N/A
52 Week Low
$10.53
$4.71
52 Week High
$39.71
$14.06

Technical Indicators

Market Signals
Indicator
ASMB
EBS
Relative Strength Index (RSI) 48.99 43.90
Support Level $27.10 $7.73
Resistance Level $30.58 $8.54
Average True Range (ATR) 1.38 0.35
MACD -0.12 0.04
Stochastic Oscillator 44.63 24.61

Price Performance

Historical Comparison
ASMB
EBS

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About EBS Emergent Biosolutions Inc.

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Share on Social Networks: